Department of Research and Development, Central Blood Institute, Blood Service Headquarters, Japanese Red Cross Society, Tokyo, Japan.
Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Transfusion. 2022 Nov;62(11):2304-2313. doi: 10.1111/trf.17128. Epub 2022 Sep 30.
Transfusion of cold-stored platelet concentrates (CS-PCs) appears effective in massively bleeding patients. However, few studies have evaluated their in vivo hemostatic function in severe thrombocytopenia.
The in vivo function of plasma-depleted human PCs was evaluated in rabbits with a blocked reticuloendothelial system and busulfan-induced thrombocytopenia. On day 1, a human apheresis PC was processed in a platelet additive solution (PAS-PC) and split evenly for cold or room temperature storage (RTS). On days 3, 6, or 9, RTS- or CS-PAS-PCs were transfused (4.0 × 10 platelets/kg) after plasma depletion into two to four rabbits that developed adequate thrombocytopenia (<25 × 10 /L). Ear bleeding time was measured by two incisions in small veins. The hemostatic rate was defined as the percentage of rabbits achieving bleeding cessation within 600 s at either incision. The experiment was repeated using five different PCs on each storage day.
The mean pre-transfusion rabbit platelet count was 8.6 ± 5.2 × 10 /L. The hemostatic rates with RTS- and CS-PAS-PCs were both 100% on day 3, 93 ± 15% and 73 ± 15% on day 6 (p = .07), and 65 ± 36% and 73 ± 37% on day 9 (p = .27), respectively, with no statistical differences. Total platelet counts were significantly lower after CS-PAS-PC than RTS-PAS-PC transfusion on all days (e.g., 58.7 ± 5.7 vs. 42.4 ± 14.7 × 10 /L, p = .0007, day 9), and did not reach 50 × 10 /L in several experiments. Platelet count increments correlated significantly with hemostatic efficacy for CS-PAS-PC transfusion only.
CS-PAS-PCs might achieve similar hemostasis as RTS-PAS-PCs in thrombocytopenic patients with mild bleeding. Hemostatic efficacy could be improved by transfusing more CS-PAS-PCs.
冷存血小板浓缩物(CS-PCs)的输注在大出血患者中似乎有效。然而,很少有研究评估其在严重血小板减少症患者中的体内止血功能。
采用阻断网状内皮系统和白消安诱导的血小板减少症兔模型,评估经血浆去除处理的人血小板的体内功能。在第 1 天,将人单采血小板在血小板添加剂溶液(PAS-PC)中处理,并平均分为冷存或室温保存(RTS)。在第 3、6 或 9 天,将 RTS 或 CS-PAS-PC 在血浆去除后输注(4.0×10 个血小板/kg)至 2 至 4 只发展为足够血小板减少症(<25×10/L)的兔。耳静脉切开术测量耳出血时间。止血率定义为两个切口在 600 秒内止血的兔子百分比。在每个储存日使用五个人血小板重复该实验。
平均输注前兔血小板计数为 8.6±5.2×10/L。在第 3 天,RTS 和 CS-PAS-PC 的止血率均为 100%,第 6 天分别为 93±15%和 73±15%(p=0.07),第 9 天分别为 65±36%和 73±37%(p=0.27),无统计学差异。在所有天,CS-PAS-PC 输注后总血小板计数均显著低于 RTS-PAS-PC 输注(例如,第 9 天分别为 58.7±5.7 和 42.4±14.7×10/L,p=0.0007),且在几次实验中未达到 50×10/L。CS-PAS-PC 输注的血小板计数增加与止血效果显著相关。
CS-PAS-PCs 可能在轻度出血的血小板减少症患者中与 RTS-PAS-PCs 达到相似的止血效果。通过输注更多的 CS-PAS-PCs,可以提高止血效果。